Skip to main content

Detection of Drug-Resistant Pulmonary Tuberculosis and Its Epidemics

  • Chapter
  • First Online:
Diagnostic Imaging of Drug Resistant Pulmonary Tuberculosis
  • 50 Accesses

Abstract

Timely detection of drug-resistant pulmonary is the vital step in controlling drug-resistant tuberculosis, and earlier detection of more patients with drug-resistant pulmonary tuberculosis is a powerful measure to reduce the spread of this disease. Moreover, earlier detection of drug-resistant pulmonary tuberculosis means lesser severity of pulmonary lesions with lesser pulmonary injuries. Lesser quantity and categories of drug-resistant tubercle bacillus are related to easier treatment with cheaper expenses. The earlier control and eradication of infectious source is performed, the lesser spreading of the drug-resistant bacteria among populations. The later the drug-resistant pulmonary tuberculosis is detected, the more prolonged course of disease will be, with progressing pulmonary lesions and greater pulmonary injuries. The increase in quantity and categories of drug-resistant tubercle bacillus in lungs means the decrease in susceptible drugs available with higher ratio of unresponsiveness to the treatment. The severe disease may develop into pulmonary destruction with a great impact on pulmonary function, leading to respiratory failure and endangering the life. Early detection and treatment for drug-resistant pulmonary tuberculosis, therefore, is of great benefits for both patients and the whole society [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Zong Z-j, Jing W, Huo F-m, et al. Resistance analysis of extensively drug-resistant Mycobacterium tuberculosis isolates against linezolid [J/CD]. Electron J Emerg Infect Dis. 2017;2(3):160–3.

    Google Scholar 

  2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update [EB/OL]. Geneva: World Health Organization; 2011. https://apps.who.int/iris/handle/10665/44597.

    Google Scholar 

  3. World Health Organization. Global tuberculosis report 2021 [EB/OL]. [2021-10-14]. https://www.who.int/publications/digital/global-tuberculosis-report-2021.

  4. World Health Organization. Global tuberculosis report 2019 [EB/OL]. Geneva: World Health Organization; 2019. https://apps.who.int/iris/handle/10665/329368.

    Google Scholar 

  5. World Health Organization. WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTB/RIF ultra compared to Xpert MTB/RIF [EB/OL]. Geneva: World Health Organization; 2017. https://apps.who.int/iris/handle/10665/254792.

    Google Scholar 

  6. Cao Y, Parmar H, Gaur RL, et al. Xpert MTB/XDR: a 10-color reflex assay suitable for point-of-care settings to detect isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from Mycobacterium tuberculosis-positive sputum [J]. J Clin Microbiol. 2021;59(3):e02314–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Crudu V, Stratan E, Romancenco E, et al. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances [J]. J Clin Microbiol. 2012;50(4):1264–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Jian J, Yang X, Yang J, et al. Evaluation of the GenoType MTBDRplus and MTBDRsl for the detection of drug-resistant Mycobacterium tuberculosis on isolates from Beijing, China [J]. Infect Drug Resist, 2018, 11: 1627–1634.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Jiao WW, Liu ZG, Han R, et al. Prevalence of drug resistant Mycobacterium tuberculosis among children in China [J]. Tuberculosis (Edinb). 2015;95(3):315–20.

    Article  PubMed  Google Scholar 

  10. State Health Commission of the People’s Republic of China, diagnostic criteria for pulmonary tuberculosis (WS 288-2017) [J/CD]. Electron J Emerg Infect Dis. 2018;3(1):59–61.

    Google Scholar 

  11. Lombardi G, Pellegrino MT, Denicolo A, et al. Quantiferon-TB performs better in children, including infants, than in adults with active tuberculosis: a multicenter study [J]. J Clin Microbiol. 2019;57(10):e01048–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. World Health Organization. HIV-associated tuberculosis. 2014.

    Google Scholar 

  13. Wang, Yi-xiang, Myung Jin Chung, Aliaksandr Skrahin, et al. Literature analysis of radiological signs related to multidrug-resistant tuberculosis [J/CD] Electron J Emerg Infect Dis, 2018,3(2):244-253.

    Google Scholar 

  14. Yu W, Tan W-g, Lu P-x. Classification and imaging manifestations of drug-resistant pulmonary tuberculosis [J/CD]. Electron J Emerg Infect Dis. 2019;4(1):42–7.

    Google Scholar 

  15. Chunrong L, Hongxia F, Puxuan L, et al. The global tuberculosis report 2021: key data analysis for China and the global world [J/CD]. Electron J Emerg Infect Dis. 2021;6(4):368–72.

    Google Scholar 

  16. Ministry of Health of the People’s Republic of China. Information compilation for sampling survey of national tuberculosis epidemiology 1979 [M]. 1981.

    Google Scholar 

  17. Ministry of Health of the People’s Republic of China. Information compilation for sampling survey of national tuberculosis epidemiology 1984/1985 [M]. 1988.

    Google Scholar 

  18. Ministry of Health of the People’s Republic of China. Information compilation for sampling survey of national tuberculosis epidemiology 1990 [M]. 1992.

    Google Scholar 

  19. Ministry of Health of the People’s Republic of China. Information compilation for sampling survey of national tuberculosis epidemiology 2000 [M]. 2002.

    Google Scholar 

  20. Ministry of Health of the People’s Republic of China. Information compilation for sampling survey of national tuberculosis epidemiology 2010 [M]. 2012.

    Google Scholar 

  21. Gao Q, Mei J. No reasons but transmission results in the high drug resistance rate of tuberculosis in China [J]. Chin J Antituberc. 2015;37(11):1091–6.

    Google Scholar 

  22. Gao Q, Yang C. Recent transmission of tuberculosis in China and its controlling strategies [J]. J Tuberc Lung Health. 2017;6(13):193–8.

    Google Scholar 

  23. Shen X, DeRiemer K, Yuan ZA, et al. Drug-resistant tuberculosis in drug-resistant pulmonary tuberculosis in Shanghai, China, 2000–2006: prevalence, trends and risk factors [J]. Int J Tuberc Lung Dis. 2009;13(2):253–9.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 People's Medical Publishing House, PR of China

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zhang, F., Yi, Yx., Lu, Hz., An, Q., Yu, Z., Lu, PX. (2023). Detection of Drug-Resistant Pulmonary Tuberculosis and Its Epidemics. In: Lu, PX., Lu, Hz., Yi, Yx. (eds) Diagnostic Imaging of Drug Resistant Pulmonary Tuberculosis. Springer, Singapore. https://doi.org/10.1007/978-981-99-8339-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-8339-1_2

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-8338-4

  • Online ISBN: 978-981-99-8339-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics